

---

# **Guidance for Industry**

## **Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers**

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)**

**July 2005  
Pharmacology and Toxicology**

# Guidance for Industry

## Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers

*Additional copies are available from:*

*Office of Training and Communications  
Division of Drug Information, HFD-240  
Center for Drug Evaluation and Research  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, MD 20857  
(Tel) 301-827-4573  
<http://www.fda.gov/cder/guidance/index.htm>*

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)**

**July 2005  
Pharmacology and Toxicology**

## TABLE OF CONTENTS

I.	INTRODUCTION.....	1
II.	BACKGROUND .....	2
III.	OVERVIEW OF THE ALGORITHM.....	3
IV.	STEP 1: NO OBSERVED ADVERSE EFFECT LEVEL DETERMINATION.....	5
V.	STEP 2: HUMAN EQUIVALENT DOSE CALCULATION.....	6
	A. Conversion Based on Body Surface Area .....	6
	B. Basis for Using mg/kg Conversions .....	7
	C. Other Exceptions to mg/m <sup>2</sup> Scaling Between Species .....	8
VI.	STEP 3: MOST APPROPRIATE SPECIES SELECTION.....	9
VII.	STEP 4: APPLICATION OF SAFETY FACTOR.....	9
	A. Increasing the Safety Factor .....	10
	B. Decreasing the Safety Factor .....	11
VIII.	STEP 5: CONSIDERATION OF THE PHARMACOLOGICALLY ACTIVE DOSE.....	12
IX.	SUMMARY .....	12
	REFERENCES.....	13
	GLOSSARY.....	15
	APPENDIX A:.....	16
	Analysis of Allometric Exponent on HED Calculations.....	16
	APPENDIX B:.....	18
	Analysis of Body Weight Effects on HED Calculations .....	18
	APPENDIX C:.....	24
	Derivation of the Interspecies Scaling Factor $(W_a/W_h)^{(1-b)}$ .....	24
	APPENDIX D:.....	25
	Examples of Calculations for Converting Animal Doses to Human Equivalent Doses.....	25
	APPENDIX E:.....	27
	Selection of Maximum Recommended Starting Dose for Drugs Administered Systemically to Normal Volunteers .....	27

*Contains Nonbinding Recommendations*

## **Guidance for Industry<sup>1</sup>**

# **Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers**

This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

## **I. INTRODUCTION**

This guidance outlines a process (algorithm) and vocabulary for deriving the maximum recommended starting dose (MRSD) for *first-in-human* clinical trials of new molecular entities in adult healthy volunteers, and recommends a standardized process by which the MRSD can be selected. The purpose of this process is to ensure the safety of the human volunteers.

The goals of this guidance are to: (1) establish a consistent terminology for discussing the starting dose; (2) provide common conversion factors for deriving a human equivalent dose (HED); and (3) delineate a strategy for selecting the MRSD for adult healthy volunteers, regardless of the projected clinical use. This process is depicted in a flow chart that presents the decisions and calculations used to generate the MRSD from animal data (see Appendix E).

FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

---

<sup>1</sup> This guidance has been prepared by the Office of New Drugs in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration.

## *Contains Nonbinding Recommendations*

### **II. BACKGROUND**

The process identified in this guidance pertains to determining the MRSD for adult healthy subjects when beginning a clinical investigation of any new drug or biological therapeutic that has been studied in animals. This guidance is not pertinent to endogenous hormones and proteins (e.g., recombinant clotting factors) used at physiologic concentrations or prophylactic vaccines. The process outlined in this guidance pertains primarily to drug products for which systemic exposure is intended; it does not address dose escalation or maximum allowable doses in clinical trials.

Although the process outlined in this guidance uses administered doses, observed toxicities, and an algorithmic approach to calculate the MRSD, an alternative approach could be proposed that places primary emphasis on animal pharmacokinetics and modeling rather than dose (Mahmood et al. 2003; Reigner and Blesch 2002). In a limited number of cases, animal pharmacokinetic data can be useful in determining initial clinical doses.<sup>2</sup> However, in the majority of investigational new drug applications (INDs), animal data are not available in sufficient detail to construct a scientifically valid, pharmacokinetic model whose aim is to accurately project an MRSD.

Toxicity should be avoided at the initial clinical dose. However, doses should be chosen that allow reasonably rapid attainment of the phase 1 trial objectives (e.g., assessment of the therapeutic's tolerability, pharmacodynamic or pharmacokinetic profile). All of the relevant preclinical data, including information on the pharmacologically active dose, the full toxicologic profile of the compound, and the pharmacokinetics (absorption, distribution, metabolism, and excretion) of the therapeutic, should be considered when determining the MRSD. Starting with doses lower than the MRSD is always an option and can be particularly appropriate to meet some clinical trial objectives.

---

<sup>2</sup> If the parent drug is measured in the plasma at multiple times and is within the range of toxic exposures for two or more animal species, it may be possible to develop a pharmacokinetic model predicting human doses and concentrations and to draw inferences about safe human plasma levels in the absence of prior human data. Although quantitative modeling for this purpose may be straightforward, the following points suggest this approach can present a number of difficulties when estimating a safe starting dose. Generally, at the time of IND initiation, there are a number of unknowns regarding animal toxicity and comparability of human and animal pharmacokinetics and metabolism: (1) human bioavailability and metabolism may differ significantly from that of animals; (2) mechanisms of toxicity may not be known (e.g., toxic accumulation in a peripheral compartment); and/or (3) toxicity may be due to an unidentified metabolite, not the parent drug. Therefore, relying on pharmacokinetic models (based on the parent drug in plasma) to gauge starting doses would require multiple untested assumptions. Modeling can be used with greatest validity to estimate human starting doses in special cases where few underlying assumptions would be necessary. Such cases are exemplified by large molecular weight proteins (e.g., humanized monoclonal antibodies) that are intravenously administered, are removed from circulation by endocytosis rather than metabolism, have immediate and detectable effects on blood cells, and have a volume of distribution limited to the plasma volume. In these cases, allometric, pharmacokinetic, and pharmacodynamic models have been useful in identifying the human mg/kg dose that would be predicted to correlate with safe drug plasma levels in nonhuman primates. Even in these cases, uncertainties (such as differences between human and animal receptor sensitivity or density) have been shown to affect human pharmacologic or toxicologic outcomes, and the use of safety factors as described in this guidance is still warranted.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.